Sagimet Biosciences Inc. (Nasdaq:SGMT)
Health Care/Life Sciences • Biotechnology
CIK 1400118
Company
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Address
155 Bovet Road
Suite 303
San Mateo, California 94402
155 Bovet Road
Suite 303
San Mateo, California 94402
Employees
10
10
Stock Info
Close
$3.6600
$3.6600
Day Range
3.4000 - 3.6986
3.4000 - 3.6986
52 Week Range
2.3900 - 7.4100
2.3900 - 7.4100
Average volume
942.15K
942.15K
Short Interest
5.47M (02/14/25)
5.47M (02/14/25)
% of Float Shorted
23.52%
23.52%
Market Cap
$112.27M
$112.27M
Revenue
$2M
$2M
Net Income
-$27.88M
-$27.88M
2020 Sales Growth
N/A
N/A
Key Executives
Board Of Directors
Executive Chairman George W. Kemble |
President, Chief Executive Officer & Director David A. Happel |
Independent Director Timothy P. Walbert |
Independent Director Paul W. Hoelscher |
Independent Director Jennifer A. Jarrett |
Independent Director Anne M. Phillips |
Independent Director Merdad V. Parsey |
Independent Director Elizabeth Grammer |
Independent Director Beth C. Seidenberg |
SEC filings
Date | Form | Event |
---|---|---|
14 Nov, 2024 | 10-Q | |
14 Nov, 2024 | 8-K | |
14 Nov, 2024 | SC 13G/A | |
14 Nov, 2024 | SC 13G/A | |
14 Nov, 2024 | SC 13G/A | |
14 Nov, 2024 | SC 13G | |
26 Aug, 2024 | EFFECT | |
22 Aug, 2024 | CORRESP | |
19 Aug, 2024 | UPLOAD | |
16 Aug, 2024 | 8-K | |
15 Aug, 2024 | S-3 | |
14 Aug, 2024 | 10-Q | |
14 Aug, 2024 | 8-K | |
5 Aug, 2024 | 4 | |
5 Aug, 2024 | 3 | |
5 Aug, 2024 | 3 | |
5 Aug, 2024 | 4 | |
1 Aug, 2024 | 8-K | |
25 Jul, 2024 | 4 | |
23 Jul, 2024 | 144 | |
23 Jul, 2024 | 4 | |
23 Jul, 2024 | 4 | |
23 Jul, 2024 | 4 | |
2 Jul, 2024 | 8-K | |
13 Jun, 2024 | 8-K/A | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
7 Jun, 2024 | 4 | |
6 Jun, 2024 | 8-K | |
23 May, 2024 | 8-K | |
15 May, 2024 | 8-K | |
15 May, 2024 | 10-Q | |
8 May, 2024 | 4 | |
8 May, 2024 | 3 | |
6 May, 2024 | 8-K | |
18 Apr, 2024 | DEFA14A | |
18 Apr, 2024 | ARS | |
18 Apr, 2024 | DEF 14A | |
3 Apr, 2024 | 4 | |
3 Apr, 2024 | 3 | |
3 Apr, 2024 | 3 | |
3 Apr, 2024 | 4 | |
28 Mar, 2024 | 4 | |
25 Mar, 2024 | 10-K | |
25 Mar, 2024 | S-8 | |
25 Mar, 2024 | 8-K | |
11 Mar, 2024 | SC 13G/A | |
14 Feb, 2024 | SC 13G | |
14 Feb, 2024 | SC 13G | |
14 Feb, 2024 | SC 13G | |
14 Feb, 2024 | SC 13G | |
9 Feb, 2024 | SC 13G/A | |
5 Feb, 2024 | SC 13G | |
2 Feb, 2024 | 8-K | |
2 Feb, 2024 | 3 | |
31 Jan, 2024 | 4 | |
31 Jan, 2024 | 4 | |
31 Jan, 2024 | 4 | |
31 Jan, 2024 | 4 | |
31 Jan, 2024 | 4 | |
30 Jan, 2024 | 8-K | |
29 Jan, 2024 | 424B4 | |
25 Jan, 2024 | EFFECT | |
24 Jan, 2024 | S-1/A | |
24 Jan, 2024 | 8-K | |
23 Jan, 2024 | S-1 | |
23 Jan, 2024 | CORRESP | |
23 Jan, 2024 | CORRESP | |
22 Jan, 2024 | 8-K | |
16 Jan, 2024 | UPLOAD | |
10 Jan, 2024 | DRS | |
29 Dec, 2023 | 8-K | |
8 Dec, 2023 | 4 | |
21 Nov, 2023 | 8-K | |
21 Nov, 2023 | 4 | |
21 Nov, 2023 | 4 | |
21 Nov, 2023 | 4 | |
21 Nov, 2023 | 4 | |
20 Nov, 2023 | 4 | |
13 Nov, 2023 | 10-Q | |
13 Nov, 2023 | 8-K | |
23 Oct, 2023 | 8-K | |
27 Sep, 2023 | 8-K | |
11 Sep, 2023 | SC 13G | |
8 Sep, 2023 | 4 | |
21 Aug, 2023 | 8-K | |
21 Aug, 2023 | 10-Q | |
10 Aug, 2023 | 8-K | |
27 Jul, 2023 | 8-K | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
20 Jul, 2023 | 4 | |
18 Jul, 2023 | 8-K | |
17 Jul, 2023 | S-8 | |
17 Jul, 2023 | 424B4 | IPO completed |
14 Jul, 2023 | SEC STAFF | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | CERT | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | S-1MEF | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
13 Jul, 2023 | 3 | |
11 Jul, 2023 | CORRESP | |
11 Jul, 2023 | 8-A12B | |
11 Jul, 2023 | CORRESP | |
10 Jul, 2023 | CORRESP | |
10 Jul, 2023 | S-1/A | |
6 Jul, 2023 | SEC STAFF | |
6 Jul, 2023 | UPLOAD | |
3 Jul, 2023 | S-1/A | |
23 Jun, 2023 | S-1 | |
15 May, 2023 | SEC STAFF | |
11 May, 2023 | DRS/A | |
10 May, 2023 | DRSLTR | |
25 Apr, 2023 | DRSLTR | |
25 Apr, 2023 | DRS/A | |
20 Apr, 2023 | UPLOAD | |
24 Mar, 2023 | DRS | |
21 Mar, 2022 | RW | |
10 May, 2021 | S-1/A | |
16 Apr, 2021 | S-1 | |
11 Mar, 2021 | DRS | |
5 Jan, 2021 | D |
Last update:2025-03-06 12:24:42.816470
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.